This study looked at the safety and effectiveness of targeted therapies or immune checkpoint inhibitors (immunotherapy) in combination with stereotactic radiotherapy in patients with renal cell carcinoma (RCC).
There were 53 patients in the study, of whom 32% were treated with immunotherapy and 68% targeted therapy. About a third of patients on targeted therapy paused their treatment while having stereotactic radiotherapy, while none of the patients on immunotherapy paused theirs. Survival was no different between the two groups.
This retrospective study suggested that tarted therapy and immunotherapy are safe for patients having stereotactic radiotherapy for the treatment of metastases from RCC. Further prospective studies are needed to identify the best treatment for patients with metastatic RCC.